美国
证券 和交易所佣金
华盛顿，特区。20549
表格
(标记一个)
| 根据1934年证券交易法第13或15(d)条规定的季度报告 |
截至季度结束
或者
| 根据1934年证券交易所法第13或15（d）节，报告过渡期从 到 |
委员会文件号
（符合其宪章规定的准确名称）
（住所的州或其他司法辖区 文件号码） |
（国税局雇主 (主要 执行人员之地址) | |
| (主要 执行人员之地址) | (邮政 编 码) |
注册人的电话号码，包括区号：(585)768-2513
根据法案第12(b)节注册的证券:
| 每一类别的名称 | 交易符号: |
在每个交易所注册的名称 | ||
| 股 股票市场 有限责任公司 | ||||
| 股 股票市场 有限责任公司 |
请在复选框中表明注册者是否：（1）在过去的12个月内（或更短的时间段，注册者应当提交此类报告）已经提交所有根据证券交易所法第13或第15（d）款所需提交的报告；并且（2）在过去的90天内一直受到这类提交要求的影响。 是 ☐
请勾选是否在过去12个月内（或更短时间）根据规则要求提交了要求提交的每个交互式数据文件。
在勾选标记处表示注册人是大型加速提交人、加速提交人、非加速提交人、小型报告公司还是新兴增长公司。请参阅证券交易法120亿条规则中“大型加速提交人”、“加速提交人”、“小型报告公司”和“新兴增长公司”的定义。
| 大型加速文件提交人 | ☐ | 加速文件提交人 | ☐ | |||
| ☒ | 小型报告公司 | |||||
| 新兴成长公司 |
如果
一家新兴成长型公司，用勾号表示注册人是否选择不使用延长的过渡期来遵守规定
以及根据《交易法》第13（a）条规定的任何新的或修订的财务会计准则。
请在核对标记处注明注册人是否为空壳公司（如交易所法案12b-2条所定义）。是☐
截至2024年12月5日，有 每股普通股的面值为$每股面值为$13的本公司普通股股票于截至2023年9月30日和2022年9月30日三个月内的运营报告中，分别已发行并流通，股份均为180,641,272股。
目录
| 页面 | ||
| 第一部分。 | 财务信息 | |
| 项目 1. | 基本报表 | |
| 截至2024年3月31日（未经审计）的合并简式资产负债表，以及截至2023年12月31日的资产负债表 | 1 | |
| 未经审计的合并简式损益表，截止到2024年和2023年3月31日的三个月 | 2 | |
| 未经审计的合并简式临时股本变动表和股东赤字，截止到2024年和2023年3月31日的三个月 | 3 | |
| 未经审计的合并现金流量表，截止至2024年3月31日和2023年3月31日的三个月数据 | 4 | |
| 基本报表未经审核简明合并财务报表注脚 | 5 | |
| 项目 2. | 管理层对财务状况和业绩的讨论与分析 | 15 |
| 项目 3. | 市场风险的定量和定性披露。 | 21 |
| 项目 4. | 内部控制及程序 | 21 |
| 第二部分。 | 其他资讯 | 22 |
| 项目 1. | 法律诉讼 | 22 |
| 项目 1A | 风险因素 | 22 |
| 项目 2. | 股票权益的未注册销售和资金用途 | 22 |
| 项目 3. | 优先证券违约 | 22 |
| 项目 4. | 矿业安全披露 | 22 |
| 项目 5. | 其他资讯 | 22 |
| 项目 6. | 展品 | 22 |
| 签名 | 23 | |
| i |
第一部分—财务资讯
项目 1. 基本报表
ONEMEDNET 公司
简明合并资产负债表
(以千为单位，股份和每股资料除外)
(未经审计)
三月 31日， 2024 | 2023年12月31日 | |||||||
| 资产 | ||||||||
| 流动资产: | ||||||||
| 现金及现金等价物 | $ | $ | ||||||
| 应收帐款，净额 | ||||||||
| 预付费用及其他流动资产 | ||||||||
| 流动资产总额 | ||||||||
| 不动产及设备，净额 | ||||||||
| 总资产 | $ | $ | ||||||
| 负债和股东权益不足额 | ||||||||
| 流动负债： | ||||||||
| 应付帐款及应计费用 | $ | $ | ||||||
| 递延收入 | ||||||||
| 贷款延期 | ||||||||
| PIPE票据 | ||||||||
| 递延的承销商费用应付 | ||||||||
| 授信额度 | ||||||||
| 流动负债总额 | ||||||||
| 贷款，关联方 | ||||||||
| 其他长期负债 | ||||||||
| 总负债 | ||||||||
| 承诺及不确定事项（附注12） | ||||||||
| 股东资本赤字： | ||||||||
| 普通股股本，面额$, 截至2024年3月31日和2023年12月31日授权的股份; 截至2024年3月31日和2023年12月31日已发行和流通的股份 | ||||||||
| 普通股，面值$; 授权股份数， 已发行股份数量和 截至2024年3月31日流通的股份，以及 截至2023年12月31日，已发行并流通的股份数量。 | ||||||||
| 资本溢额 | ||||||||
| 按成本核算的库藏股 和 截至2024年3月31日和2023年12月31日的股份，分别是 | ( | ) | ||||||
| 累积亏损 | ( | ) | ( | ) | ||||
| 股东权益的赤字为 | ( | ) | ( | ) | ||||
| 总负债及股东权益赤字 | $ | $ | ||||||
附注 附注为此未经审核简明综合财务报表之重要组成部分。
| 1 |
ONEMEDNET公司
精简 合并损益表
(以千计，不含股票和每股数据)
(未经审计)
| 截至3月31日的三个月结束 | ||||||||
| 2024 | 2023 | |||||||
| 收入 | ||||||||
| 订阅收入 | $ | $ | ||||||
| 网页影像营业收入 | ||||||||
| 总营业收入 | ||||||||
| 营收成本 | ||||||||
| 毛利率 | ( | ) | ( | ) | ||||
| 运营费用 | ||||||||
| 一般和行政 | ||||||||
| 销售和营销 | ||||||||
| 研发 | ||||||||
| 总营业费用 | ||||||||
| 营业损失 | ( | ) | ( | ) | ||||
| 其他费用（收益），净额 | ||||||||
| 利息支出 | ||||||||
| 认股权证公允价值变动 | ( | ) | ||||||
| PIPE票据公平值变动 | ( | ) | ||||||
| 可转换应收票据公平价值变动 | ||||||||
| 存货权证费用 | ||||||||
| 其他（收入）费用 | ( | ) | ||||||
| 其他费用总计，净额 | ||||||||
| 净亏损 | $ | ( | ) | $ | ( | ) | ||
| 每股收益: | ||||||||
| 普通股每股基本和稀释净损失 | $ | ) | $ | ) | ||||
| 基本和稀释后的平均流通股本 | ||||||||
附注是这些未经审计的简明综合财务报表的组成部分。
| 2 |
ONEMEDNET公司
压缩 综合变动表的暂时性权益和股东赤字
(以千为单位，除股票数据外)
(未经审计)
| 总计 | ||||||||||||||||||||||||||||||||||||||||
| A-2系列基金 | A-1轮 | 短期投资证券 | 额外的 | 总计 | ||||||||||||||||||||||||||||||||||||
| 优先股 | 优先股 | 股权 | 普通股 | 实收股本 | 累计 | 股东权益 | ||||||||||||||||||||||||||||||||||
| 股份 | 金额 | 股份 | 金额 | 金额 | 股份 | 金额 | 资本 | 亏损 | 亏损 | |||||||||||||||||||||||||||||||
| 截至2022年12月31日的余额 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||
| 与可转换票据一起发行OMN warrants | - | - | - | |||||||||||||||||||||||||||||||||||||
| 基于股票的薪酬费用 | - | - | - | |||||||||||||||||||||||||||||||||||||
| 净亏损 | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||
| 截至2023年3月31日的余额 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||
| 额外的 | 总计 | |||||||||||||||||||||||||||
| 普通股 | 库藏股 | 实收股本 | 累计 | 股东权益 | ||||||||||||||||||||||||
| 股份 | 金额 | 股份 | 金额 | 资本 | 亏损 | 亏损 | ||||||||||||||||||||||
| 截至2023年12月31日的余额 | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||
| 发行普通股以结清应支付的延期承销费用 | - | |||||||||||||||||||||||||||
| 基于股票的薪酬费用 | - | - | ||||||||||||||||||||||||||
| 回购普通股 | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||
| 净亏损 | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
| 截至2024年3月31日的余额 | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||
附注是这些未经审计的简明综合财务报表的组成部分。
| 3 |
ONEMEDNET公司
简明综合现金流量表
（以千为单位）
(未经审计)
| 截至3月31日的三个月结束 | ||||||||
| 2024 | 2023 | |||||||
| 经营活动现金流量： | ||||||||
| 净亏损 | $ | ( | ) | $ | ( | ) | ||
| 调整为净损失到经营活动现金流量净使用： | ||||||||
| 折旧和摊销 | ||||||||
| 基于股票的薪酬费用 | ||||||||
| 权证负债公允价值变动 | ( | ) | ||||||
| PIPE票据公平值变动 | ( | ) | ||||||
| CEBA贷款的豁免收益 | ( | ) | ||||||
| 非现金利息 | ||||||||
| 可转换应收票据公平价值变动 | ||||||||
| 存货权证费用 | ||||||||
| 经营性资产和负债的变化： | ||||||||
| 应收账款 | ( | ) | ( | ) | ||||
| 预付费用及其他流动资产 | ( | ) | ( | ) | ||||
| 应付账款和应计费用 | ||||||||
| 递延收入 | ||||||||
| 用于经营活动的净现金 | ( | ) | ( | ) | ||||
| 投资活动现金流量： | ||||||||
| 购买物业和设备 | ( | ) | ||||||
| 投资活动中使用的净现金 | ( | ) | ||||||
| 融资活动的现金流： | ||||||||
| 股东贷款发行的收益 | ||||||||
| 信用额度借款的收益 | ||||||||
| CEBA贷款的偿还 | ( | ) | ||||||
| 发行可转换债券所得款项 | ||||||||
| 业务组合成本 | ( | ) | ||||||
| 融资活动提供的净现金 | ||||||||
| 现金及现金等价物的净增加（减少） | ( | ) | ||||||
| 期初现金及现金等价物余额 | ||||||||
| 期末现金及现金等价物 | $ | $ | ||||||
| 非现金投资和筹资活动的补充披露: | ||||||||
| 发行普通股以结清应支付的延期承销费用 | $ | $ | ||||||
| 回购普通股的考虑已包含在应付账款和应计费用中 | $ | ( | ) | $ | ||||
附注是这些未经审计的简明综合财务报表的组成部分。
| 4 |
ONEMEDNET公司
简明合并财务报表附注
1. 业务描述
组织 和业务描述
OneMedNet 公司（以下简称“公司”）是一家专注于数字医疗影像管理、 交易所和共享的医疗软件公司。该公司于2015年11月20日在特拉华州成立。公司一直专注于创建简化数字医疗影像管理、交易所和共享的解决方案。 公司有一家全资子公司OneMedNet Technologies （加拿大）有限公司，成立于2015年10月16日，依据不列颠哥伦比亚省的《商业公司法》注册，功能货币为加币。公司的总部位于明尼苏达州的伊甸草坪。
在2023年11月7日，Data Knights Merger Sub, Inc.（"Merger Sub"）是一家特拉华州公司，也是Data Knights Acquisition Corp.（"Data Knights"）的全资子公司，合并到OneMedNet Solutions Corporation（前身为OneMedNet Corporation）（"Legacy ONMD"）中，Legacy ONMD作为Data Knights的全资子公司存续（"业务合并"）。在业务合并完成后，Data Knights更名为“OneMedNet Corporation。”
基础 展示和合并的基础
附带的未经审计的压缩合并基本报表已按照美国通用会计原则（"U.S. GAAP"）及证券交易委员会（"SEC"）对于中期报告的规则和规定准备。根据这些规则和规定，某些通常包含在按U.S. GAAP准备的基本报表中的注释或其他财务信息已被压缩或省略。未经审计的中期压缩合并基本报表已与年度合并基本报表的准备基础相同，并且，根据管理层的意见，反映了所有调整，这些调整仅包括为公平呈现公司在所呈现中期的结果所必需的正常、经常性调整。截止到2024年3月31日的三个月运营结果并不一定代表2024年12月31日截止的年度结果或任何未来年度或中期的结果。
随附的未经审计的临时合并基本报表应与截至2023年12月31日的年度合并基本报表及相关附注一并阅读，这些内容已在我们于2024年11月5日向美国证券交易委员会提交的《10-K表格（修订稿）》中列出。
截至2023年10月的 未经审计的临时合并基本报表包括本公司的全资子公司 OneMedNet Technologies (Canada) Inc. 所有重要的内部交易在合并中已被消除。
流动性 和持续经营
公司自成立以来一直产生经常性净亏损，包括截至2024年3月31日和2023年3月31日的$
To continue in existence and expand its operations, the Company will be required to, and management plans to, raise additional working capital through an equity or debt offering and ultimately hopes to attain profitable operations to fulfill its operating and capital requirements for at least 12 months from the date of the issuance of the condensed consolidated financial statements. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to continue receiving working capital cash payments and generating cash flow from operations.
| 5 |
Risks and uncertainties
The Company is subject to risks common to companies in the markets it serves, including, but not limited to, global economic and financial market conditions, fluctuations in customer demand, acceptance of new products, development by its competitors of new technological innovations, dependence on key personnel, and protection of proprietary technology.
Segment information
The Company operates in one operating segment and, accordingly, no segment disclosures have been presented herein.
2. Summary of Significant Accounting Policies
Except as described below, the accounting policies of the Company are set forth in Note 2 to the consolidated financial statements contained in the Form 10-K/A, and the accounting policies followed by the Company for interim financial reporting are consistent with the accounting policies therein.
Treasury stock
The Company records the repurchase of its common stock, par value $ per share (“Common Stock”) at cost on the trade date of the transaction. These shares are considered treasury stock, which is a reduction to stockholders’ equity. Treasury stock is included in authorized and issued shares but excluded from outstanding shares.
Emerging growth company status
The Company is an “emerging growth company”, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can take advantage of an extended transition period for complying with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (1) is no longer an emerging growth company or (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act.
Accounting pronouncements not yet adopted
In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740) (“ASU 2023-09”). ASU 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. ASU 2023-09 is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the impact of adopting ASU 2023-09.
在2023年11月，FASB发布了ASU No. 2023-07， 分部报告（主题 280）：报告服务部门（主题 280）变更披露方式，通过升级对意义重大的分部费用的披露来改进分部报告披露要求。该准则适用于 2023 年 12 月 15 日之后的财年和 2024 年 12 月 15 日之后的财年间隔期。该准则必须适用于财务报表中呈现的所有期间的追溯。该公司目前正在评估该标准对合并财务报表的影响。, 这项标准旨在增强细分披露，即使对于只有一个可报告细分的实体也是如此。特别是， 该标准将要求定期披露提供给首席运营决策maker的重要细分费用，并包括在每个报告的细分利润和损失的衡量中。该标准还要求按可报告细分披露所有其他细分项目以及其组成的描述。最后，该标准将要求披露首席运营决策maker的职称和职位，并解释首席运营决策maker如何利用报告的细分利润或损失的衡量来评估细分绩效以及决定如何分配资源。该标准适用于在2023年12月15日之后开始的年度期间，以及在2024年12月15日之后开始的年度期间内的中期。允许提前采用。公司目前正在评估该标准对其合并基本报表及附注的影响。
最近采纳的会计准则
2023年12月，FASB发布了ASU No. 2023-08， 无形资产-商誉和其他-加密资产（主题350-60）：对加密资产的会计处理和披露 (“ASU 2023-08”美国公证会计准则2023-08要求每个报告期对某些加密资产进行公允价值计量，公平价值变动反映在净利润中。修订还要求披露每个重要加密资产的名称、公允价值、持有单位和成本基础，以及加密资产持有量的年度对账。新指南适用于2024年12月15日之后开始的财政年度和这些财政年度内的中期时段，可以提前采纳。公司选择在2024年1月1日提前采纳此指南。截至2024年3月31日的三个月结束日，公司采用美国公证会计准则2023-08对财务报表的整合未产生影响。
| 6 |
3. 可转换债务
可转换可转让票据
从2019年到2023年，公司向相关和不相关的投资者发行了多种可转换票据，这些票据可以在下一次股权融资交易中转换为Legacy ONMD的股权证券（以下简称“可转换票据”）。可转换票据的利率为
可转换票据是为了一般营运资金目的而发行的。公司选择在ASC 825下的公允价值选项（“FVO”） 金融工具，用于其可转换票据。在FVO选举下，金融工具最初按其发行日估计的公允价值进行计量，并在每个报告期的日期按估计的公允价值进行定期重新计量。公允价值的估计调整作为其他（收入）费用中的一项单行项目呈现在附带的合并损益表中，标题为可转换债务公允价值变动.
在 2023年11月，所有可转换承诺票据根据其与Data Knights和Legacy ONMD之间的业务合并的条款被转换，并在2023年12月31日后不再存在。有关在2023年12月31日之前发行的可转换承诺票据的所有其他详细信息，请参见10-K/A表格。
管道 备注
在
2023年6月28日，
公司选定将其PIPE票据记入公允价值选择权会计。估计的公允价值调整被呈现为附带的损益表中的一项其他（收入）费用净额，标明为PIPE票据公允价值变动。截至2024年3月31日和2023年12月31日，PIPE票据的公允价值为$
股东贷款
在2024年1月，公司收到来自关联方投资者的股东贷款总收益为$
海伦娜 笔记
在2024年3月28日，公司 与Helena Global Investment Opportunities 1 Ltd.（“Helena”），Cayman Islands的一家顾问和投资者Helena Partners Inc.的关联公司签署了最终证券购买协议（“Helena SPA”），该协议提供了最多$
根据
海伦娜终止协议，公司向海伦娜发行了一份购买认股权证
| 7 |
4. Line of Credit
In
March 2024, the Company obtained a line of credit of $
5. Canadian Emergency Business Loan Act (“CEBA”)
During
December 2020, the Company applied for and received a $
6. Stockholders’ Deficit
Common Stock
就业务合并一事，Data Knights与承销商（“EF Hutton”）达成协议，其中EF Hutton同意放弃在收盘时应支付的相关合并承销费用（$
在2024年2月，公司与一位可转债的前持有人签署了一份股票回购协议，依据该协议，公司回购了 普通股的
优先股
截至2024年3月31日， 优先股发行或流通。所有旧版ONMD A-2系列优先股和A-1系列优先股股票已在业务组合中转换为普通股。有关2023年12月31日前发行的A-2系列优先股和A-1系列优先股的所有其他详细信息，请参阅Form 10-K/A。
| 8 |
截至2024年3月31日和2023年3月31日的三个月，计算基本和摊薄每股净亏损所使用的普通股加权平均发行股份数量是相同的。在计算截至2024年3月31日和2023年3月31日的三个月的摊薄每股净亏损时，公司排除了以下潜在的稀释性证券，因其影响将是反稀释的，并且降低每个期间计算的每股净亏损：
三个月 结束 3月31日 | ||||||||
| 2024 | 2023 | |||||||
| 购买普通股的期权 | ||||||||
| 未归属的限制性股票单位和奖励 | ||||||||
| 普通股权证 | ||||||||
| A系列-1优先股 | ||||||||
| A-2系列优先股 | ||||||||
| 可转换的可转换票据 | ||||||||
| 总计 | ||||||||
| 截至三月三十一日的三个月 | ||||||||
| 2024 | 2023 | |||||||
| 营业成本 | $ | $ | ||||||
| 一般 和行政 | ||||||||
| 销售与市场营销 | ||||||||
| 研发成本 | ||||||||
| 总 基于股票的薪酬费用 | $ | $ | ||||||
股权 激励计划 – 摘要
在2023年，公司采用了OneMedNet Corporation 2022年股票激励计划（“2022计划”）和 预留了相当于 2022计划在业务合并关闭时立即生效，并取代了传统的ONMD股票激励计划。
股权 激励计划 – 期权
截至2024年3月31日和2023年3月31日的三个月内，公司记录的基于股票的补偿费用为$ 千和$ 千， 分别适用于其未行使的期权。
股权 激励计划 – 限制性股票单位（“RSU”）
For the three months ended March 31, 2024 and 2023, the Company recorded stock-based compensation expense of $ thousand and $ thousand, respectively, on its outstanding restricted stock units.
9. Stock Warrants
The Company has the following warrants outstanding for the periods presented:
| As of | ||||||||
March 31, 2024 | December 31, 2023 | |||||||
| Liability Classified Warrants | ||||||||
| Private Placement Warrants | ||||||||
| PIPE Warrants | ||||||||
| Subtotal | ||||||||
| Equity Classified Warrants | ||||||||
| Public Warrants | ||||||||
| Subtotal | ||||||||
| Grand Total | ||||||||
| 9 |
Convertible Promissory Notes Warrants
As
described in Note 3, the Company issued Convertible Promissory Notes Warrants in 2022 and 2023. The Convertible Promissory Notes
Warrants are classified as equity in accordance with ASC subtopic 815-40, Derivatives and Hedging - Contracts in Entity’s
Own Equity (“ASC 815-40”). The Company determined that the fair value of the combined instrument (inclusive of the
Convertible Promissory Notes) significantly exceeds the proceeds received; therefore, the Company concluded that the Convertible Promissory Notes Warrants are
most accurately portrayed as an issuance cost related to the Convertible Promissory Notes. This resulted in an expense of $
In
connection with the closing of the Business Combination on November 7, 2023, all Convertible Promissory Notes Warrants were cashless
exercised into shares of Legacy ONMD common stock and exchanged based on the appropriate conversion ratio for the Common Stock less an
exercise price of $
PIPE Warrants
In
conjunction with the issuance of the PIPE Notes described in Note 3, Data Knights also issued and sold to each of the Purchasers
warrants to purchase Common Stock at an exercise price of $
Private Placement Warrants
关于2023年11月7日业务合并的完成，公司承担了
10. 公允价值衡量
下表列出了公司的资产和负债，这些资产和负债按照定期基础计量公平价值，包括关联方（以千计）。
| 2024年3月31日 | ||||||||||||||||
| 一级 | 二级 | 三级 | 总计 | |||||||||||||
| 负债： | ||||||||||||||||
| 认股权证 | $ | $ | $ | $ | ||||||||||||
| PIPE认股权 | ||||||||||||||||
| PIPE备忘录 | ||||||||||||||||
| 总负债，按公允价值计量 | $ | $ | $ | $ | ||||||||||||
| 2023年12月31日 | ||||||||||||||||
| 一级 | 二级 | 三级 | 总计 | |||||||||||||
| 负债： | ||||||||||||||||
| 认股权证 | $ | $ | $ | $ | ||||||||||||
| PIPE认股权 | ||||||||||||||||
| PIPE 注记 | ||||||||||||||||
| 总负债，按公允价值计量 | $ | $ | $ | $ | ||||||||||||
| 10 |
下表展示了截至2024年3月31日的三个月期间，私人warrants、PIPE票据和PIPE warrants在公允价值下的变化（单位：千美元）：
| 三级展期： | 私人 认购权证 | 私有投资（PIPE） 附注 | 私有投资（PIPE） 认购权证 | |||||||||
| 2023年12月31日余额 | ||||||||||||
| 公允价值变动 | ( | ) | ( | ) | ||||||||
| 2024 年 3 月 31 日余额 | $ | $ | $ | |||||||||
私募 配售warrants和PIPE warren
定向增发认股权证和PIPE认股权证的总公允价值为$
| 截至2024年3月31日， | ||||||||
| 2024 | ||||||||
| 私有投资（PIPE） | 私人 | |||||||
| 认购权证 | 认购权证 | |||||||
| 股票价格 | $ | $ | ||||||
| 行使价格 | $ | $ | ||||||
| 预期波动率 | % | % | ||||||
| 加权平均无风险利率 | % | % | ||||||
| 预期股息收益率 | ||||||||
| 预期期限（以年为单位） | ||||||||
管道 备注
这些PIPE票据的估计公允价值是根据某些可能场景的聚合概率加权平均结果确定的。然后，这些结果的概率加权平均值的总和被折现回每个报告期，在每种情况下，基于估计的隐含折现率，按风险调整的折现率进行折现。鉴于与公司相关的事实模式和发展阶段，折现率在估值期间保持不变。
PIPE票据的公允价值截至2024年3月31日为$
11. 关联方交易
PIPE票据和认股权证
Data
Knights在业务组合过程中发行并出售PIPE票据，这些票据可转换为普通股。 从PIPE票据筹集的总款项为$
与PIPE票据的发行相关，公司还发行了总共
可转换的应付票据和认股权证
如第3条所述，公司向相关方投资者发行了多种可转换票据。与相关方的可转换票据所募集的总收入为$
| 11 |
Shareholder Loans
In
addition to the convertible shareholder loans described in Note 3, the Company also received gross proceeds of $
| As of | ||||||||
March 31, 2024 | December 31, 2023 | |||||||
| Shareholder loans – nonconvertible | $ | $ | ||||||
| Shareholder loans – convertible | ||||||||
| Accrued interest | ||||||||
| Total shareholder loans | $ | $ | ||||||
Loan Extensions
The
Company assumed Data Knights’ liabilities, which included existing loan extensions to related parties. The loan extensions were
to be either repaid in cash or, at the option of the lender, exchanged for a fixed amount of Common Stock at a price of $ per share
upon the closing of a business combination or a similar event. At the closing of the Business Combination, all lenders provided notice
to have their loans converted into shares upon the filing of a registration statement on Form S-1 with the SEC. As of March 31, 2024,
a registration statement has not yet been declared effective by the SEC, and a balance of $
12. Commitments and Contingencies
Lease Agreement
The
Company has a month-to-month lease for its headquarters space at a cost of $
Litigation
From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recognized, if and when it is probable that a liability has been incurred and the amount can be reasonably estimated. The Company was not subject to any material legal proceedings during the three months ended March 31, 2024 and 2023.
13. Subsequent Events
The Company has evaluated subsequent events occurring through December 5, 2024, the date the condensed consolidated financial statements were issued, for events requiring recording or disclosure in the Company’s condensed consolidated financial statements.
Shareholder Loans
From
April 2024, through the date of this report, the Company received gross proceeds of $
Private Placements
As
described in Note 3, on June 14, 2024, the Company and Helena entered into the Helena Termination Agreement to terminate the Helena SPA
and related documents. Pursuant to the Helena Termination Agreement, the Company issued to Helena a warrant to purchase
| 12 |
On
July 23, 2024 and July 25, 2024, the Company entered into securities purchase agreements (the “Securities Purchase Agreements”)
with certain institutional investors in connection with the private placement of its Common Stock and pre-funded warrants with aggregate
gross proceeds of approximately $
Pursuant
to the Securities Purchase Agreements, the Company agreed to issue and sell to the investors shares of its Common Stock at
a price of $ per share, pre-funded warrants exercisable for
On
September 24, 2024, the Company entered into a securities purchase agreement (the “Follow-on SPA”) with an institutional
accredited investor in connection with the private placement of its Common Stock, warrants and pre-funded warrants with aggregate gross
proceeds of approximately $
Pursuant
to the Follow-on SPA, the Company agreed to issue and sell to the investor shares of its Common Stock at a price of $ per
share, warrants exercisable for shares of its Common Stock at an exercise price of $
Standby Equity Purchase Agreement
On
June 17, 2024, the Company entered into a standby equity purchase agreement (the “SEPA”) with YA II PN, LTD, a Cayman Islands
exempt limited partnership managed by Yorkville Advisors Global, LP (“Yorkville”). Pursuant to the SEPA, subject to certain
conditions, the Company has the option to sell to Yorkville an aggregate amount of up to $
Any
purchase under an advance would be subject to certain limitations, including that Yorkville will not purchase or acquire any shares that
would result in it and its affiliates beneficially owning more than % of the then outstanding voting power or number of shares of
Common Stock or any shares that when aggregated with shares issued under all other earlier advances, would exceed
| 13 |
In
connection with the execution of the SEPA, the Company paid a $
Additionally,
Yorkville agreed to advance to the Company, in exchange for a convertible promissory note (the “Yorkville Promissory Note”),
a principal amount of $
The Yorkville Promissory Note may be accelerated by Yorkville upon specified events of default, and may become amortizable for cash if (i) the daily VWAP is less than the Floor Price for five trading days during a period of seven consecutive trading days, (ii) the Company has issued in excess of 95% of the shares of Common Stock available under the Exchange Cap or (iii) the Company is in material breach of its obligations under a registration rights agreement it entered into with Yorkville in connection with the SEPA or Yorkville becomes limited in its ability to freely resell shares subject to an advance as further described in the Yorkville Promissory Note, subject to de-amortization after certain cures.
Yorkville Letter
On October 8, 2024, Yorkville sent the Company a letter notifying the Company that it had breached a registration rights agreement with Yorkville by failing to file a Registration Statement on Form S-1 on the timeline set forth in the registration rights agreement (the “Yorkville Letter”). The Yorkville Letter asserted that this breach was an event of default and an amortization event under the prepaid advance in connection with the SEPA. The Yorkville Letter also asserted that the Company’s failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 was an event of default under the Yorkville Promissory Note. The Company subsequently engaged in discussions with Yorkville regarding the Yorkville Letter, which discussions are ongoing.
Pursuant to the Yorkville Promissory Note, upon the occurrence of an amortization event, the Company is required to pay all principal and accrued interest on the Yorkville Promissory Note, plus a 10% payment premium on the principal amount, in equal installments over 3 calendar months or until the amortization event is cured, whichever is earlier. In addition, upon the occurrence of an event of default, the interest rate on the Yorkville Promissory Note increases to 18% retroactive to the date of the event of default.
Executive Turnover
As previously announced on Form 8-K, on August 26, 2024, Lisa Embree, Chief Financial Officer, Executive Vice President, Treasurer and Secretary, notified the Company of her intention to resign from her position effective August 30, 2024.
Effective
August 30, 2024, the Board of Directors of the Company (the “Board”) appointed Mr. Robert Golden to serve as the Chief Financial
Officer (“CFO”) on an interim basis to fill the vacancy created by the resignation of Lisa Embree. Effective on his appointment
as interim CFO, Mr. Golden stepped down as a member and the chair of the Audit Committee of the Board. In connection with his appointment
as interim CFO, the Company entered into a consulting agreement with Mr. Golden, pursuant to which Mr. Golden will receive a $
As
previously announced on a Current Report on Form 8-K filed with the SEC on October 8, 2024, on October 1, 2024, Paul J. Casey and Erkan
Akyuz resigned from the Board, effective immediately. Also on October 1, 2024, the Board appointed Jair Clarke and Sherry Coonse McCraw
to the Board to fill the vacancies created by Mr. Casey and Mr. Akyuz, respectively. In connection with Ms. Coonse McCraw and Mr. Clarke’s
service on the Board, the Board approved an RSU grant providing for the grant of
| 14 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis are intended to help you understand our business, financial condition, results of operations, liquidity, and capital resources. You should read this discussion in conjunction with the Company’s consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q (this “Report”) and in the Form 10-K/A.
In addition to historical financial analysis, this discussion and analysis contains forward-looking statements based upon current expectations that involve risks, uncertainties, and assumptions, as described under the heading “Cautionary Note Regarding Forward Looking Statements.” Actual results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of various factors, risks and uncertainties, including those set forth under “Risk Factors” included elsewhere (or incorporated by reference) in this Report and in the Form 10-K/A. Unless the context otherwise requires, references in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” to “OneMedNet”, “we”, “us”, “our,” and “the Company” are intended to mean the business and operations of OneMedNet Corporation and its consolidated subsidiary following the Business Combination.
Company Overview
OneMedNet Corporation is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. The Company was founded in Delaware on November 20, 2015. The Company has been solely focused on creating solutions that simplify digital medical image management, exchange, and sharing. The Company has one wholly-owned subsidiary, OneMedNet Technologies (Canada) Inc., incorporated on October 16, 2015 under the provisions of the Business Corporations Act of British Columbia whose functional currency is the Canadian dollar. The Company’s headquarters location is Eden Prairie, Minnesota.
Business Combination
On November 7, 2023, we held the closing of the Business Combination whereby Merger Sub merged with and into Legacy ONMD, with Legacy ONMD continuing as the surviving entity, which resulted in all of the issued and outstanding capital stock of Legacy ONMD being exchanged for shares of Common Stock upon the terms set forth in the agreement and plan of merger, dated April 25, 2022 (the “Merger Agreement”), by and among Data Knights, Merger Sub, Legacy ONMD, Data Knights, LLC, a Delaware limited liability company (the “Sponsor”), and Paul Casey, in his capacity as representative of the stockholders of Legacy ONMD. The Business Combination and other transactions that closed on November 7, 2023, pursuant to the Merger Agreement, led to Data Knights changing its name to “OneMedNet Corporation” and the business of the Company became the business of Legacy ONMD.
Pursuant to the terms of the Merger Agreement, the total consideration for the Business Combination and related transactions (the “Merger Consideration”) was approximately $200 million. In connection with the special meeting of stockholders of Data Knights, certain public holders holding 1,600,741 shares of Data Knights common stock exercised their right to redeem such shares for a pro rata portion of the funds held by Continental Stock Transfer & Trust Company, as trustee in the trust account established in connection with Data Knights’ initial public offering. Effective November 7, 2023, Data Knights’ units ceased trading, and effective November 8, 2023, the Common Stock began trading on the Nasdaq Global Market under the symbol “ONMD” and the Public Warrants began trading on the Nasdaq Global Market under the symbol “ONMDW.” The Common Stock and Public Warrants were transferred from The Nasdaq Global Market to The Nasdaq Capital Market at the opening of business on August 19, 2024, and continue to trade under the symbols “ONMD” and “ONMDW,” respectively.
As a result of the Business Combination, holders of Data Knights common stock automatically received Common Stock of OneMedNet, and holders of Data Knights warrants automatically received warrants of OneMedNet with substantively identical terms. At the closing of the Business Combination, all shares of Data Knights owned by the Sponsor (consisting of shares of Data Knights common stock and shares of Data Knights Class B common stock), automatically converted into an equal number of shares of OneMedNet’s Common Stock, and the private placement warrants held by the Sponsor automatically converted into warrants to purchase one share of OneMedNet Common Stock with substantively identical terms.
| 15 |
Key Components of Consolidated Statements of Operations
Revenue
The Company generates revenue from two streams: (1) iRWD, which provides regulatory grade imaging and clinical data in the pharmaceutical, device manufacturing, contract research organizations, and AI markets and (2) BEAM, which is a medical imaging exchange platform between hospital/healthcare systems, imaging centers, physicians and patients. iRWD is sold on a fixed fee basis based on the number of data units and the cost per data unit committed to in the customer contract. Revenue is recognized when the data is delivered to the customer. BEAM revenue is subscription-based revenue that is recognized ratably over the subscription period committed to by the customer. The Company invoices its BEAM customers quarterly or annually in advance with the customer contracts automatically renewing unless the customer issues a cancellation notice.
The Company excludes from revenue taxes collected from a customer that are assessed by a governmental authority and imposed on and concurrent with a specific revenue-producing transaction. The transaction price for the products is the invoiced amount. Advanced billings from contracts are deferred and recognized as revenue when earned. Deferred revenue consists of payments received in advance of performance under the contract. Such amounts are generally recognized as revenue over the contractual period. The Company receives payments from customers based upon contractual billing schedules. Accounts receivable is recorded when the right to consideration becomes unconditional. Payment terms on invoiced amounts typically range from zero to 90 days, with typical terms of 30 days.
Cost of Revenue
Our cost of revenue is composed of our distinct performance obligations of hosting, labor, and data cost.
General and Administrative
General and administrative functions include finance, legal, human resources, operations, and information technology support. These functions include costs for items such as salaries and benefits and other personnel-related costs, maintenance and supplies, professional fees for external legal, accounting, and other consulting services, and depreciation expense.
Research and Development
Costs incurred in the research and development of our products are expensed as incurred. Research and development costs include personnel, contracted services, materials, and indirect costs involved in the design and development of new products and services, as well as hosting expense.
Sales and Marketing
Our sales and marketing costs consist of labor and tradeshow costs.
Interest Expense
Interest expense consists of interest incurred on shareholder loans.
Other (Income) Expenses, Net
Other (income) expenses, net, primarily includes the changes in fair value of convertible debt and change in fair value of PIPE Notes for which we have elected the fair value option of accounting. Convertible notes payable, which include convertible promissory notes and PIPE Notes issued to related parties, including accrued interest and contingently issuable warrants, contain embedded derivatives, including settlement of the contingent conversion features, which require bifurcation and separate accounting. Accordingly, we have elected to measure the entire contingently convertible debt instruments, including accrued interest, at fair value. These debt instruments were initially recorded at fair value as liabilities and are subsequently re-measured at fair value on our condensed consolidated balance sheet at the end of each reporting period and at settlement, as applicable. Other income or expenses, net, also includes changes in fair value of loan extensions, deferred underwriting fees and warrants which are treated as liability instruments measured at fair value for accounting purposes, initially recorded at fair value and subsequently re-measured to fair value on our condensed consolidated balance sheets at the end of each reporting period. The changes in the fair value of these debt and liability instruments are recorded in changes in fair value, included as a component of other (income) expenses, net, in the condensed consolidated statements of operations.
At the closing of the Business Combination, convertible promissory notes were converted into Common Stock immediately prior to the Closing and were no longer outstanding as of the closing date.
Other (income) expenses, net, also includes foreign exchange and tax expenses related to the Company’s operations and revenue outside of the United States.
| 16 |
Results of Operations
The following table sets forth our condensed consolidated statements of operations data for the periods presented:
Three Months Ended March 31, | Change | |||||||||||||||
| 2024 | 2023 | $ | % | |||||||||||||
| Revenue | ||||||||||||||||
| Subscription revenue | $ | 201 | $ | 167 | $ | 34 | 20 | % | ||||||||
| Web imaging revenue | 47 | 33 | 14 | 42 | % | |||||||||||
| Total revenue | 248 | 200 | 48 | 24 | % | |||||||||||
| Cost of revenue | 317 | 289 | 28 | 10 | % | |||||||||||
| Gross margin | (69 | ) | (89 | ) | 20 | -22 | % | |||||||||
| Operating expenses | ||||||||||||||||
| General and administrative | 1,358 | 539 | 819 | 152 | % | |||||||||||
| Sales and marketing | 229 | 259 | (30 | ) | -12 | % | ||||||||||
| Research and development | 445 | 582 | (137 | ) | -24 | % | ||||||||||
| Total operating expenses | 2,032 | 1,380 | 652 | 47 | % | |||||||||||
| Loss from operations | (2,101 | ) | (1,469 | ) | (632 | ) | 43 | % | ||||||||
| Other (income) expense, net | ||||||||||||||||
| Interest expense | 42 | - | 42 | N/A | ||||||||||||
| Change in fair value of warrants | (7 | ) | - | (7 | ) | N/A | ||||||||||
| Change in fair value of PIPE Notes | (20 | ) | - | (20 | ) | N/A | ||||||||||
| Change in fair value of convertible promissory notes | - | 4,414 | (4,414 | ) | -100 | % | ||||||||||
| Stock warrant expense | - | 1,935 | (1,935 | ) | -100 | % | ||||||||||
| Other (income) expense | (7 | ) | 8 | (15 | ) | -188 | % | |||||||||
| Total other (income) expenses, net | 8 | 6,357 | (6,349 | ) | -100 | % | ||||||||||
| Net loss | $ | (2,109 | ) | $ | (7,826 | ) | $ | 5,717 | -73 | % | ||||||
Revenue
Three Months Ended March 31, | Change | |||||||||||||||
| 2024 | 2023 | $ | % | |||||||||||||
| Subscription revenue (BEAM) | $ | 201 | $ | 167 | $ | 34 | 20 | % | ||||||||
| Web imaging revenue (iRWD) | 47 | 33 | 14 | 42 | % | |||||||||||
| Total | $ | 248 | $ | 200 | $ | 48 | 24 | % | ||||||||
Our revenue is comprised of sales made from our subscription revenue (BEAM) and from our web imaging (iRWD). For the three months ended March 31, 2024, overall revenue increased by 24%. The primary driver for the subscription revenue increase was delivery of revenue to a significant customer. The primary driver for the increase in web imaging revenue was revenue deliveries pushed to the first quarter of 2024.
Cost of Revenue
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Cost of revenue | 317 | 289 | ||||||
| % of revenue | 128 | % | 145 | % | ||||
For the three months ended March 31, 2024, we were able to reduce our cost of revenue as a percentage of revenue by 17%. The decrease is primarily driven by lower iRWD consulting costs during the three months ended March 31, 2024.
| 17 |
General and Administrative
Our general and administrative expense increased $0.8 million, or 152%, to $1.4 million for the three months ended March 31, 2024 from $0.5 million for the three months ended March 31, 2023. The increase is primarily due to an increase in professional fees of $0.6 million from being a public company, employee salaries and benefits of $0.1 million and bad debt expense of $0.1 million.
Sales and Marketing
Our sales & marketing expense decreased $30 thousand, or 12%, to $229 thousand for the three months ended March 31, 2024 from $259 thousand for the three months ended March 31, 2023. The decrease is primarily due to a decrease in salaries and benefits of $84 thousand, which is partially offset by increases in trade shows, dues and subscriptions and consultants, which collectively increased by $54 thousand.
Research and development
Our research and development expense decreased $0.1 million, or 24%, to $0.5 million for the three months ended March 31, 2024 from $0.6 million for the three months ended March 31, 2023. The decrease is primarily due to a decrease in stock compensation expense of $0.2 million, which is partially offset by an increase in salaries and benefits of $0.1 million.
Interest Expense
During the three months ended March 31, 2024, interest expense was primarily comprised of interest expense on loans made from related parties (Management and Directors) and interest expense on $0.5 million of deferred underwriter fees payable in cash. During the three months ended March 31, 2023, we did not incur any interest expense.
Change in Fair Value of Warrants
The change in fair value of Warrants was due to the closing of the Business Combination and the resulting fluctuations in the market price of shares of Common Stock.
Change in Fair Value of PIPE Notes
The change in fair value of PIPE Notes was due to the closing of the Business Combination and the resulting fluctuations in the market price of shares of Common Stock.
Change in Fair Value of Convertible Debt
The change in fair value of convertible debt was due to the closing of the Business Combination and the resulting fluctuations of the market price of shares of Common Stock. The Convertible Promissory Notes were no longer outstanding during the three months ended March 31, 2024.
Non-GAAP Financial Measure
In addition to providing financial measurements based on U.S. GAAP, we provide an additional financial metric that is not prepared in accordance with U.S. GAAP (a “non-GAAP financial measure”). We use this non-GAAP financial measure, in addition to U.S. GAAP financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes, to measure executive compensation, and to evaluate our financial performance. This non-GAAP financial measure is Adjusted EBITDA, as discussed below.
我们相信，这一非通用会计准则财务指标反映了我们业务的持续展开，使得可以进行有意义的比较和分析业务趋势，因为它有助于跨会计期间以及与同行公司的财务结果进行比较。我们还认为，这一非通用会计准则财务指标使得投资者能够评估我们的运营结果和未来前景，就像我们自己所做的那样。这一非通用会计准则财务指标可能排除在性质上不同寻常、不时发生或不反映我们持续运营结果的费用和收益。
这个非美国通用会计准则财务指标不应被视为美国通用会计准则财务指标的替代，可能与其他公司使用的同名非美国通用会计准则财务指标有所不同。此外，非美国通用会计准则财务指标存在局限性，因为它排除了必须包含在美国通用会计准则报告中的费用和收入。因此，非美国通用会计准则财务指标不能替代我们按照美国通用会计准则报告的财务指标，并且只能作为我们根据美国通用会计准则呈报的财务业绩的补充，而非替代品。美国通用会计准则净损失是最接近的可比美国通用会计准则指标。
| 18 |
我们认为调整后的EBITDA是衡量我们业务运营实力和表现的重要指标，也是衡量我们历史经营趋势的良好指标。调整后的EBITDA排除了我们不认为是核心业务的项目。我们将调整后的EBITDA定义为不包括以下项目的美国通用会计准则净亏损：利息费用；所得税费用；有形资产的折旧和摊销；股份补偿；业务合并交易费用；以及可能不时出现的其他非经常性项目。
非通用会计调整以及我们排除它们的非通用财务指标的依据如下：
| ● | 调整后的EBITDA不反映利息费用或股东贷款所需的现金支付，这并非我们业务的核心融资方式； | |
| ● | 调整后的EBITDA不反映与我们的外国子公司相关的所得税费用，因为自成立以来我们一直遭受整体运营亏损，并预计将来也会继续如此； | |
| ● | 尽管折旧和摊销是不计入现金的支出，但我们目前折旧和摊销的资产未来可能需要更换，并且调整后的EBITDA不反映资金支出以满足这种更换的需求； | |
| ● | 调整后的EBITDA不包括股权报酬费用，这对我们的业务是重要的一部分，且在可预见的未来将继续是一项重大的经常性非现金支出，并且是我们薪酬策略的重要组成部分； | |
| ● | 调整后的EBITDA不反映由我们的管理层不认为是我们持续经营的指示的收益或费用产生的影响。然而，其中一些费用和收益（如市场调整、股票认股权费用等）是反复出现且可能会再次出现；和 | |
| ● | 其他公司，包括我们行业的公司，可能以不同方式计算调整后的EBITDA，这降低了其作为比较指标的实用性。 |
下表对比了美国公认会计原则（GAAP）净亏损与调整后的EBITDA在所呈现期间的 reconciliation（单位：千美元）：
| 截至3月31日的三个月结束 | ||||||||
| 2024 | 2023 | |||||||
| 净亏损 | $ | (2,109 | ) | $ | (7,826 | ) | ||
| 利息支出 | 42 | - | ||||||
| 折旧和摊销 | 11 | 6 | ||||||
| 基于股票的补偿 | 137 | 368 | ||||||
| 认股权证公允价值变动 | (7 | ) | - | |||||
| PIPE票据公平值变动 | (20 | ) | - | |||||
| 可转换应收票据公平价值变动 | - | 4,414 | ||||||
| 存货权证费用 | - | 1,935 | ||||||
| 调整后的EBITDA | (1,946 | ) | (1,103 | ) | ||||
流动性和资本资源
截至2024年3月31日，我们的主要流动资金来源是来自关联方投资者的收益、循环信贷额度以及客户支付的现金。
下表显示了所列期间内用于经营活动的净现金及现金等价物、用于投资活动的净现金及现金等价物，以及通过融资活动提供的净现金及现金等价物：
| 截至3月31日的三个月结束 | ||||||||
| 2024 | 2023 | |||||||
| 经营活动产生的净现金流量 | ||||||||
| 经营活动 | $ | (1,547 | ) | $ | (1,002 | ) | ||
| 投资活动 | (6 | ) | - | |||||
| 筹资活动 | 1,680 | 876 | ||||||
| 19 |
运营活动
我们的 在经营活动中使用的净现金及现金等价物包括经调整后的净损失，该损失考虑了某些非现金项目，包括折旧 和摊销、基于股票的薪酬费用、分类为负债的金融工具的公允价值变动，以及 经营资产和负债的变动。流动资本项目的主要变化，如应收账款 和递延收入的变化，源于客户与我们之间合同履行义务支付时间的差异。 这可能导致在此期间操作现金流的来源或使用，取决于所收到的款项支付时间与 履行履行义务的比较。
截至2024年3月31日的三个月内，经营活动净现金使用为150万美元。经营活动净现金使用 是由于我们210万美元的净亏损，这被100000美元的非现金项目抵消，主要包括基于股票的补偿， 以及由于向供应商付款时间和客户收款时间的现金流动情况造成的40万美元的经营资产和负债的现金。
相比之下，公司在截至2023年3月31日的三个月内，运营活动使用的净现金为100万美元。 截至2023年3月31日的三个月内，运营活动使用的净现金是由于我们的净亏损为780万美元， 这一亏损被非现金项目670万美元抵消，主要包括可转换债务公允价值变化440万美元、股票期权支出190万美元和股票基础补偿支出40万美元，以及由于向供应商支付现金和从客户收取现金的时间安排导致的运营资产和负债的现金为0.1万美元。
投资活动
我们的投资活动主要包括房地产和设备购买。
2024年3月31日三个月期间用于投资活动的净现金及现金等价物包括0.6万美元的购买房地产和设备。
相比之下，在截至2023年3月31日的三个月期间，没有现金及现金等价物被用于或提供给投资活动。
融资活动
2024年3月31日结束的三个月，融资活动提供的净现金为170万美元，主要包括相关方贷款的130万美元和循环信贷的40万美元。
相比之下，公司在截至2023年3月31日的三个月内通过融资活动提供的净现金为90万美元，主要由110万美元的可转换票据发行所得抵消20万美元的业务组合费用。
合同 义务和承诺及持续经营展望
目前，管理层认为我们的现金及现金等价物不足以满足我们在未来12个月内可预见的现金需求。除了我们的经常性营业费用外，我们的可预见现金需求还包括支持我们制造行业和员工扩张的预期资本支出、利息费用和最低合同义务。管理层打算通过债务和股权发行来筹集运营所需的现金。因此，由于公司经常性经营亏损以及对资金的额外需求来支持其营业和资本要求，存在关于公司能否维持足够流动性的重大不确定性，这使得公司持续经营的能力受到相当大的怀疑。
我们未来的资本需求将取决于许多因素，包括我们的增长率、支持研究和开发工作的支出时机和范围、销售和市场活动的扩展、新产品和服务的推出与提升，以及未来收购科技或企业的成本。如果需要外部融资，我们可能无法在可接受的条件下筹集所有基金类型，甚至可能根本无法筹集。
| 20 |
以下表格总结了截至2024年3月31日我们当前和开多期的现金需求：
| 应付款项： | ||||||||||||
| 总计 | 少于1年 | 1-3年 | ||||||||||
| 应付账款和应计费用 | $ | 5,874 | $ | 5,874 | $ | - | ||||||
| 贷款延期 | 2,992 | 2,992 | - | |||||||||
| 应付的承销商费用 | 3,307 | 3,307 | - | |||||||||
| 关联方借款 | 1,777 | - | 1,777 | |||||||||
| PIPE 注记 | 1,617 | 1,617 | - | |||||||||
| 授信额度 | 411 | 411 | - | |||||||||
| $ | 15,979 | $ | 14,202 | $ | 1,777 | |||||||
关键会计政策和估计
我们的 管理层对财务状况和运营结果的讨论与分析是基于我们的综合财务 报表，这些报表是根据一般公认会计原则（GAAP）编制的。在准备我们的基本报表时，我们做出了估计、假设和 判断，这些因素可能会对我们的营业收入、运营结果以及净利润或亏损产生显著影响，也会影响到 我们的资产负债表上某些资产和负债的价值，这些是在报告期间内及截至报告期时的情况。这些估计、假设和 判断是必要的，因为未来事件及其对我们运营结果和资产价值的影响无法确定，并且是基于我们的历史经验以及其他我们认为在这种情况下合理的假设进行的。 随着新事件的发生或获取更多信息，这些估计可能会改变，我们可能会定期面临不确定性， 这些不确定性的结果不在我们的控制范围内，可能会在较长一段时间内无法得知。由于在财务报告过程中使用估计是固有的，实际结果可能与这些估计有所不同。
有关我们关键会计估计的讨论，请参见在10-K/A表格中的“管理层讨论与财务状况及经营成果分析”，以及在10-K/A表格中所列的审计基本报表的附注，和本报告其他地方所包含的基本报表附注。到2024年3月31日，这些关键会计政策和估计没有发生重大变化，和在10-K/A表格中讨论的内容一致。
最近发布和采用的会计原则
最近发布的会计公告的描述，可能会影响我们的财务状况和经营业绩，已在本报告其他部分的注释2中披露，包含在我们的合并基本报表中。
项目3. 关于市场风险的定量和定性披露
我们是一家受到Exchange Act规则12b-2定义为较小报告公司的公司，不需要提供此项目要求的信息。
条款4.控件与程序
披露控制和程序的评估
我们的管理层在首席执行官和首席财务官的参与下，评估了截至2024年3月31日我们的披露控制和程序的设计和控件的有效性（根据证券交易法第13a-15(e)和15d-15(e)条款的定义）。基于该评估，首席执行官和首席财务官得出结论，截至2024年3月31日，我们的披露控制和程序并不有效，因为我们的财务报告内部控制存在重大缺陷，未能正确设计，以确保能妥善识别非常规交易并确保适当的职责划分。
材料 软弱
如本报告其他部分所述，我们于2023年11月7日完成了业务合并。在业务合并之前，我们的前身Data Knights是一家特殊目的收购公司，成立的目的是进行与一家或多家企业的合并、资本股票交换、资产收购、股票购买、资本重组或类似业务结合。因此，之前的内部控制在评估日期时不再适用或不够全面，因为在业务合并之前，Data Knights的运营与合并后实体的运营相比微不足道。因此，管理层意识到公司内部控制在用户访问/职责分离、缺乏正式控制环境和对财务报告控件的监督、在非例行交易中的会计错误以及缺乏记录保存方面存在重大缺陷。由于目前经验的成交量有限，加上我们的财务限制，我们目前没有扩展的会计部门来更好地分离职责。随着时间的推移，随着我们继续增长并增加会计人员，我们预计将持续增强我们的内部控制结构，包括适当的职责分离。在2024年9月，进行了会计人员的变更，以增强我们的财务报告结构，我们预计这将减轻报告压力，包括非例行交易的报告。此外，新人员专注于创建中央档案库来管理会计记录和其他公司文件。
基本报表的控件内部审计控制的变化。
截至2024年3月31日结束的三个月内，我们的财务报告内部控制没有发生任何变化，这些变化可能对我们的内部控制有实质性影响，或者有可能对我们的内部控制产生实质性影响。
| 21 |
PART II - 其他信息
项目1。法律诉讼
我们 可能不时会面临各种索赔、诉讼和其他因正常 业务而产生的法律和行政程序。这些索赔、诉讼和其他程序中的一些可能涉及高度复杂的问题，这些问题存在着实质性的不确定性， 并可能导致损害赔偿、罚款、处罚、非货币制裁或救济。目前我们没有参与任何法律程序， 在管理层看来，如果对我们不利的裁决将单独或合并对我们的业务、经营结果、财务状况或现金流产生重大不利影响。
事项1A.风险因素。
除了本报告中列出的其他信息外，您还应仔细考虑在10-K/A表格和我们其他公开文件中讨论的“风险因素”，这些因素可能对我们的业务、财务控件或未来业绩产生重大影响。此前在10-K/A表格和我们其他公开文件中的“风险因素”中没有发生重大变化。
如果您还未使用您的moomoo账户，请使用它查看该功能。
2024年3月31日结束的三个月内，我们没有销售未在《8-k表格》中事先包括的未注册证券。
项目3. 对高级证券的违约。
无。
项目4. 煤矿安全披露。
不适用。
项目5. 其他信息。
在2024年3月31日结束的三个月中，公司的任何董事或高管
项目 6. 附件。
本季度报告（表格10-Q）附带的文件如下：
随附提交。
# 附在本季度报告表格10-Q中的附件32.1和附件32.2所提供的认证被视为附随此报告，并且 不应被视为为1934年证券交易法第18节所规定的“提交”，除非 注册人特别通过引用将其纳入。
| 22 |
签名
根据1934年证券交易法的要求，注册人已正式授权下述签署人员于2024年12月5日代表其签署本报告。
| OneMedNet公司 | ||
| 由： | /s/ 罗伯特·戈尔登 | |
| 罗伯特 戈尔登 | ||
| 临时首席财务官 （授权官员和信安金融及会计官员） | ||
| 23 |